November 2019 Vol 12, No 7

Predicting Success in Population Health

David B. Nash, MD, MBA

November 2019 Vol 12, No 7 - Editorial

Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

David Campbell, PharmD, MS, Marlo Blazer, PharmD, BCOP, Lisa Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA

November 2019 Vol 12, No 7 - Business, Business, Original Research, Original Research

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

by James T. Kenney, RPh, MBA

Key Trends in Healthcare for 2020 and Beyond

F. Randy Vogenberg, PhD, John Santilli, MBA

November 2019 Vol 12, No 7 - Industry Trends

The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population

Nihar R Desai, MD, MPH, Pamala Reed, DrPH, MPH, Paula J Alvarez, RPh, MBA, MPH, Jeanene Fogli, PhD, RD, Steven D Woods, PharmD, Mary Kay Owens, RPh, CPh

November 2019 Vol 12, No 7 - Business, Original Research

Stakeholder Perspective

The Impact of Quality Care on a Medicaid Population with Hyperkalemia

by Byron C. Scott, MD, MBA

FDA Oncology Update

November 2019 Vol 12, No 7 - FDA Approvals

Results 1 - 5 of 5